宮田　遥 (ミヤタ　ハルカ)

医学研究院助教
北海道大学病院助教
Last Updated :2026/03/10

■研究者基本情報

学位

  • 医学博士, 北海道大学, 2021年06月

Researchmap個人ページ

ホームページURL

研究者番号

  • 80962878

J-Global ID

担当教育組織

■研究活動情報

論文

  • Decision regret after curative treatment and its association with the decision-making process and quality of life for prostate cancer patients.
    Miho Sato, Takahiro Osawa, Kentaro Nishioka, Tomohiko Miyazaki, Shuhei Takahashi, Takashi Mori, Takayuki Hashimoto, Haruka Miyata, Ryuji Matsumoto, Takashige Abe, Kazuki Ohashi, Sachiyo Murai, Yoichi M Ito, Nobuo Shinohara
    International journal of urology : official journal of the Japanese Urological Association, 32, 1, 95, 102, 2025年01月, ［国際誌］
    英語, 研究論文（学術雑誌）, OBJECTIVES: To determine how the treatment decision-making process and posttreatment health-related quality of life (HRQOL) are related to regret about treatment choice for prostate cancer patients in Japan. METHODS: We invited a total of 614 patients who were treated with radiation therapy (RT), radical prostatectomy (RP), or active surveillance/watchful waiting (AS/WW) from April 2007 to March 2021. Posttreatment regret was evaluated by the Decision Regret Scale. HRQOL was evaluated by the Expanded Prostate Cancer Index Composite and the 12-item Short Form Survey. The decision-making process was assessed by patient evaluation of the decision-making process. We compared the decision regret scale scores across treatment types, HRQOL, and decision-making processes. RESULTS: Data from 371 patients were analyzed (RT: 202, RP: 149, AS/WW: 20). The median length of time since treatment was 64 (IQR: 43-93) months. The decision regret scale scores were not significantly different among the treatment groups but were significantly greater (strong regret) in patients with poor urinary summary scores, bowel summary scores, and hormonal summary scores. The decision regret scale scores were significantly lower (less regret) for patients who reported being adequately informed at the time of the treatment decision and who had adequately communicated their questions and concerns to physicians than for patients who reported less adequate communication. This result was also observed among patients who reported low HRQOL scores. CONCLUSIONS: These findings underline the important influence of posttreatment HRQOL and decision-making as an interactive process between physicians and their patients on posttreatment regret in prostate cancer patients.
  • Think different in metastatic RCC treatment 免疫チェックポイント阻害薬時代におけるCytoreductive nephrectomy(CN)の意義
    大澤 崇宏, 菊地 央, 山田 修平, 宮田 遥, 松本 隆児, 安部 崇重, 篠原 信雄
    泌尿器外科, 36, 臨増, 788, 789, 医学図書出版(株), 2023年08月
    日本語
  • Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma.
    Shuhei Yamada, Haruka Miyata, Makoto Isono, Kanta Hori, Junko Yanagawa, Aiko Murai, Tomoyuki Minowa, Yuka Mizue, Kenta Sasaki, Kenji Murata, Serina Tokita, Munehide Nakatsugawa, Sadahiro Iwabuchi, Shinichi Hashimoto, Terufumi Kubo, Takayuki Kanaseki, Tomohide Tsukahara, Takashige Abe, Nobuo Shinohara, Yoshihiko Hirohashi, Toshihiko Torigoe
    Cancer immunology, immunotherapy : CII, 2023年02月16日, ［国際誌］
    英語, 研究論文（学術雑誌）, Bladder cancer is a major and fatal urological disease. Cisplatin is a key drug for the treatment of bladder cancer, especially in muscle-invasive cases. In most cases of bladder cancer, cisplatin is effective; however, resistance to cisplatin has a significant negative impact on prognosis. Thus, a treatment strategy for cisplatin-resistant bladder cancer is essential to improve the prognosis. In this study, we established a cisplatin-resistant (CR) bladder cancer cell line using an urothelial carcinoma cell lines (UM-UC-3 and J82). We screened for potential targets in CR cells and found that claspin (CLSPN) was overexpressed. CLSPN mRNA knockdown revealed that CLSPN had a role in cisplatin resistance in CR cells. In our previous study, we identified human leukocyte antigen (HLA)-A*02:01-restricted CLSPN peptide by HLA ligandome analysis. Thus, we generated a CLSPN peptide-specific cytotoxic T lymphocyte clone that recognized CR cells at a higher level than wild-type UM-UC-3 cells. These findings indicate that CLSPN is a driver of cisplatin resistance and CLSPN peptide-specific immunotherapy may be effective for cisplatin-resistant cases.
  • GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy.
    Haruka Miyata, Yoshihiko Hirohashi, Shuhei Yamada, Junko Yanagawa, Aiko Murai, Shinichi Hashimoto, Serina Tokita, Kanta Hori, Takashige Abe, Terufumi Kubo, Tomohide Tsukahara, Takayuki Kanaseki, Nobuo Shinohara, Toshihiko Torigoe
    Cancer immunology, immunotherapy : CII, 71, 4, 795, 806, 2022年04月, ［国際誌］
    英語, 研究論文（学術雑誌）, Recent studies have revealed that treatment-resistant cancer stem-like cells (CSCs)/cancer-initiating cells (CICs) can be targeted by cytotoxic T lymphocytes (CTLs). CTLs recognize antigenic peptides derived from tumor-associated antigens; thus, the identification of tumor-associated antigens expressed by CSCs/CICs is essential. Human leucocyte antigen (HLA) ligandome analysis using mass spectrometry enables the analysis of naturally expressed antigenic peptides; however, HLA ligandome analysis requires a large number of cells and is challenging for CSCs/CICs. In this study, we established a novel bladder CSC/CIC model from a bladder cancer cell line (UM-UC-3 cells) using an ALDEFLUOR assay. CSCs/CICs were isolated as aldehyde dehydrogenase (ALDH)-high cells and several ALDHhigh clone cells were established. ALDHhigh clone cells were enriched with CSCs/CICs by sphere formation and tumorigenicity in immunodeficient mice. HLA ligandome analysis and cap analysis of gene expression using ALDHhigh clone cells revealed a distinctive antigenic peptide repertoire in bladder CSCs/CICs, and we found that a glutamate receptor, ionotropic, kainite 2 (GRIK2)-derived antigenic peptide (LMYDAVHVV) was specifically expressed by CSCs/CICs. A GRIK2 peptide-specific CTL clone recognized GRIK2-overexpressing UM-UC-3 cells and ALDHhigh clone cells, indicating that GRIK2 peptide can be a novel target for bladder CSC/CIC-targeting immunotherapy.
  • Development and validation of a porcine organ model for training in essential laparoscopic surgical skills.
    Madoka Higuchi, Takashige Abe, Kiyohiko Hotta, Ken Morita, Haruka Miyata, Jun Furumido, Naoya Iwahara, Masafumi Kon, Takahiro Osawa, Ryuji Matsumoto, Hiroshi Kikuchi, Yo Kurashima, Sachiyo Murai, Abdullatif Aydin, Nicholas Raison, Kamran Ahmed, Muhammad Shamim Khan, Prokar Dasgupta, Nobuo Shinohara
    International journal of urology : official journal of the Japanese Urological Association, 2020年08月03日, ［査読有り］, ［国際誌］
    英語, 研究論文（学術雑誌）, OBJECTIVES: To develop a wet laboratory training model for learning core laparoscopic surgical skills and evaluating learners' competency level outside the operating room. METHODS: Participants completed three tasks (task 1: tissue dissection around the aorta; task 2: tissue dissection and division of the renal artery; task 3: renal parenchymal closure). Each performance was video recorded and subsequently evaluated by two experts, according to the Global Operative Assessment of Laparoscopic Skills and task-specific metrics that we developed (Assessment Sheet of Laparoscopic Skills in Wet Lab score). Mean scores were used for analyses. The subjective mental workload was also assessed (NASA Task Load Index). RESULTS: The 54 participants included 32 urologists, eight young trainees and 14 medical students. A total of 13 participants were categorized as experts (≥50 laparoscopic surgeries), eight as intermediates (10-49) and 33 as novices (0-9). There were significant differences in the Global Operative Assessment of Laparoscopic Skills and Assessment Sheet of Laparoscopic Skills in Wet Lab scores among the three groups in all three tasks. Higher NASA Task Load Index scores were observed in novices, and there were significant differences in tasks 1 (Kruskal-Wallis test, P = 0.0004) and 2 (P = 0.0002), and marginal differences in task 3 (P = 0.0745) among the three groups. CONCLUSIONS: Our training model has good construct validity, and differences in the NASA Task Load Index score reflect previous laparoscopic surgical experiences. Our findings show the ability to assess both laparoscopic surgical skills and mental workloads, which could help educators comprehend trainees' level outside the operating room. Given the decreasing opportunity to carry out pure laparoscopic surgeries because of the dissemination of robotic surgery, especially in urology, our model can offer practical training opportunities.
  • Abscopal effect following nivolumab induction in a patient with metastatic renal cell carcinoma-unique pathological features of the primary specimen: A case report.
    Kanta Hori, Yoshihiko Hirohashi, Toshiki Aoyagi, Narumi Taniguchi, Masashi Murakumo, Haruka Miyata, Toshihiko Torigoe, Takashige Abe, Nobuo Shinohara, Ken Morita
    Experimental and therapeutic medicine, 19, 3, 1903, 1907, 2020年03月, ［国際誌］
    英語, 研究論文（学術雑誌）, The case of a patient with metastatic renal cell carcinoma who exhibited the abscopal effect following treatment by anti-programmed death-1 (PD-1) antibody is presented. A 40-year-old woman was diagnosed with an 8.2-cm renal tumor without distant metastases, and radical nephrectomy was subsequently performed. Pathological examination revealed a clear cell renal cell carcinoma. At 3 months after surgery, the patient developed one lung metastasis. Following treatment with interferon and three types of tyrosine kinase inhibitors, anti-PD1 antibody (nivolumab) was started. During the treatment, para-aortic/supraclavicular lymph nodes and several lung lesions remained, although other lesions decreased markedly. The patient was subsequently treated by palliative radiotherapy to the para-aortic and supraclavicular lymph nodes for pain control. After the radiotherapy, the lung lesions previously refractory to nivolumab started to decrease, probably due to an abscopal effect. Additionally, the laboratory data and Karnofsky Performance Status improved. Histological re-examination of the primary lesion revealed heterogeneity of the immunological microenvironment, which may be associated with the heterogeneity of treatment sensitivity.
  • Prognostic impact of local radiotherapy on metastatic urothelial carcinoma patients receiving systemic chemotherapy.
    Takashige Abe, Keita Minami, Toru Harabayashi, Ataru Sazawa, Hiroki Chiba, Hiroshi Kikuchi, Haruka Miyata, Jun Frumido, Ryuji Matsumoto, Takahiro Osawa, Ishizaki Junji, Mochizuki Tango, Chiba Satoshi, Akino Tomoshige, Murakumo Masashi, Miyajima Naoto, Tsuchiya Kunihiko, Maruyama Satoru, Sachiyo Murai, Nobuo Shinohara
    Japanese journal of clinical oncology, 50, 2, 206, 213, 2020年02月17日, ［査読有り］, ［国際誌］
    英語, 研究論文（学術雑誌）, OBJECTIVE: To clarify the prognostic impact of local radiotherapy on metastatic urothelial carcinoma patients treated by systemic chemotherapy. METHODS: Of the 228 metastatic urothelial carcinoma patients treated with systemic chemotherapy, 97 received radiotherapy mainly to metastatic sites. In patients for whom the purpose of radiotherapy was not specified, more than 50 Gy irradiation was considered to be for disease consolidation for survival analysis, while less than 50 Gy was categorized as palliation. According to the Kaplan-Meier method, we analysed overall survival from the initiation of treatment for metastatic urothelial carcinoma until death or the last follow-up, using the log-rank test to assess the significance of differences. The Cox model was applied for prognostic factor analysis. RESULTS: Overall, there was no significant difference in survival between patients with and those without radiotherapy (P = 0.1532). When analysing the patients undergoing consolidative radiotherapy separately, these 25 patients showed significantly longer survival than the 72 patients with palliative radiotherapy (P = 0.0047), with a 3-year overall survival of 43.3%. Of the present cohort, 22 underwent metastasectomy for disease consolidation, and there was no overlapping case between the metastasectomy cohort and cohort receiving consolidative radiotherapy. After controlling for four independent prognostic factors (sex, performance status, haemoglobin level and number of organs with metastasis) in our previous study, radiotherapy for disease consolidation showed a marginal value (hazard ratio = 0.666, P = 0.0966), while metastasectomy remained significant (hazard ratio = 0.358, P = 0.0006). CONCLUSIONS: In the selected patients, long-term disease control could be achieved after consolidative radiotherapy for metastatic urothelial carcinoma disease. Our observations suggest that local ablative therapy (surgery or radiotherapy) could facilitate long-term disease control. However, the treatment decision should be individualized because of the lack of randomized control trials.
  • Validity assessment of the laparoscopic radical nephrectomy module of the LapVision virtual reality simulator.
    Haruka Miyata, Takashige Abe, Kiyohiko Hotta, Madoka Higuchi, Takahiro Osawa, Ryuji Matsumoto, Hiroshi Kikuchi, Yo Kurashima, Sachiyo Murai, Nobuo Shinohara
    Surgery open science, 2, 1, 51, 56, 2020年01月, ［国際誌］
    英語, 研究論文（学術雑誌）, Background: Virtual reality simulators allow trainees to perform repeated practice and provide objective dexterity metrics regarding their performance, which means that virtual reality-based surgical training is becoming a vital part of initial learning of basic laparoscopic surgical skills. However, its educational role in learning advanced procedures remains undetermined. We evaluated the validity of the laparoscopic radical nephrectomy module of the LapVision virtual reality simulator. Methods: Urologists, medical students, and a junior resident voluntarily participated in the present study, and they performed training with a laparoscopic left radical nephrectomy module. For construct validation, dexterity metrics calculated in the simulator and the mean score of Global Operative Assessment of Laparoscopic Skills evaluated by 2 experts' video review were compared according to the certification of Japanese Endoscopic Surgical Skill Qualification or previous surgical experience. Results: Ten experts (≥ 50 laparoscopic surgeries), 9 intermediates (11-49), and 14 novices (0-10) voluntarily participated in the present study. Regarding the construct validity, there was a significant difference in the total number of errors, blood loss, and Global Operative Assessment of Laparoscopic Skills score among the groups for both the Endoscopic Surgical Skill Qualification status and previous surgical experience. Conclusion: The present study demonstrated good construct validity for the LapVision nephrectomy module. Furthermore, global skill assessment was possible by experts' reviews, which indicates the usefulness of the virtual reality procedural module as a skill assessment tool. Virtual reality-based procedural simulation has marked potential to become a vital part of integrated laparoscopic training programs.
  • [Treatment Outcome of Axitinib for Metastatic Renal-Cell Carcinoma Patients].
    Naohisa Kusakabe, Takahiro Osawa, Haruka Miyata, Hiroshi Kikuchi, Ryuji Matsumoto, Satoru Maruyama, Takashige Abe, Nobuo Shinohara
    Hinyokika kiyo. Acta urologica Japonica, 64, 9, 353, 358, 2018年09月, ［査読有り］, ［国内誌］
    日本語, 研究論文（学術雑誌）, Axitinib was approved for use in Japan as a salvage therapy for patients with metastatic renal cell carcinoma (RCC) in 2012. We retrospectively evaluated the cases of 32 RCC patients that were treated with Axitinib as a 2nd- or further-line therapy between November 2012 and March 2017. Overall survival (OS), progression-free survival (PFS), and adverse events were assessed. The median OS and PFS from the initiation of Axitinib were 29 and 11 months, respectively. Nineteen patients received Axitinib as a 2nd-line treatment, in whom the median OS and median PFS were 22 and 10 months, respectively, while the median OS and PFS were 29 and 15.5 months, respectively, amongthe 13 patients who received Axitinib as a 3rd- or further-line treatment, which suggested that Axitinib is effective in the 3rd-line and further-line settings. A Cox multivariate model revealed that bone metastasis was a significant adverse factor for OS. Common grade 3 or higher adverse events included hypertension (28%), diarrhea (7%), and proteinuria (7%). Although the present study demonstrated the efficacy and safety of salvage Axitinib treatment in patients who had recurrent disease after the initial systemic therapy, further large-scale studies should be warranted to make clear its clinical effectiveness in these patients.
  • The significance of metastasectomy in patients with metastatic renal cell carcinoma
    Haruka Miyata, Nobuo Shinohara, Norihiro Murahashi, Kunihiko Tsuchiya, Naoto Miyajima, Satoru Maruyama, Takashige Abe, Kichizo Kaga, Satoshi Hirano, Katsuya Nonomura
    Acta Urologica Japonica, 61, 2, 49, 54, Editorial Board of Acta Urologica Japonica, 2015年02月01日, ［査読有り］
    日本語, 研究論文（学術雑誌）

その他活動・業績

共同研究・競争的資金等の研究課題

  • 膀胱癌幹細胞様細胞を標的とする免疫療法と化学・放射線療法との相乗効果の解明
    科学研究費助成事業
    2023年04月01日 - 2026年03月31日
    宮田 遥
    本研究の目的は膀胱癌組織において化学療法・放射線療法の前後で、1)免疫学的に重要な役割を示す分子(具体的にはHLA, PD-L1など)の発現の変化、2)CSCsの含有割合の変化（ALDH1, GRIK2をマーカーとする）、3)CSCsを標的とした免疫療法に対する感受性の変化を調べ、化学療法・放射線療法とCSCsを標的とした免疫療法の有効性との関連を証明することである。そのための研究計画として1)放射線療法・化学療法前後での膀胱癌組織の採取、2)放射線療法・化学療法前後でのHLA, PD-L1, ALDH1, GRIK2の発現量の解析、3）放射線療法・化学療法前後でのGRIK2特異的細胞障害性T細胞の反応性の解析、4)In vitroでの化学療法・放射線療法によるCSCs濃度変化とGRIK2特異的の確認, 5)In vivoでの化学療法・放射線療法と免疫療法との併用療法の効果の解析, として研究計画を立てていた。
    令和5年度は①放射線療法前後、術前補助化学療法前後の手術検体から膀胱癌組織を採取しHLA、PD-L1,癌幹細胞様細胞のマーカー発現の解析、②膀胱癌cell lineへの抗癌剤投与・放射線照射前後における癌幹細胞様細胞のマーカー発現の解析を計画していたが、研究代表者の妊娠に伴う体調不良、令和6年1月より産前産後休暇、育児休業を取得していることにより研究を進められていない状況である。
    日本学術振興会, 若手研究, 北海道大学, 23K14555

主な担当授業

  • 基本医学研究, 2024年, 修士課程, 医学院
  • 基本医学総論, 2024年, 修士課程, 医学院
  • 医学総論, 2024年, 博士後期課程, 医学院
  • 基盤医学研究, 2024年, 博士後期課程, 医学院
  • 臨床医学研究, 2024年, 博士後期課程, 医学院